Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer

por Nabhan, C, Villines, D, Valdez, T V, Tolzien, K, Lestingi, T M, Bitran, J D, Christner, S M, Egorin, M J, Beumer, J H
Publicado 2012

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker

por Munster, P N, Marchion, D, Thomas, S, Egorin, M, Minton, S, Springett, G, Lee, J-H, Simon, G, Chiappori, A, Sullivan, D, Daud, A
Publicado 2009